Tirzepatide initiation was associated with a lower risk of primary open-angle glaucoma compared with selective glucagon-like peptide-1 receptor agonists: risk ratio: 0.50
GLP-1RAs have been proposed to have anti-inflammatory properties
Twice the power for maximum cellular protection, liver detoxification, and skin luminosity
Preparation for these scenarios minimizes health risks and stress
There are several good options right now: semaglutide (Wegovy), a GLP-1 receptor agonist medication tirzepatide (Zepbound), a GLP-1/GIP medication liraglutide (Saxenda), a GLP-1 medication Several oral medications are also approved by the FDA for weight loss, including: semaglutide (oral Wegovy) orforglipron (Foundayo) phentermine (Suprenza) naltrexone-bupropion (Contrave) orlistat (Xenical/Alli) These are FDA-approved for adults who have a BMI of 30 or higher or a BMI of 27 along with a weight-related condition such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, cardiovascular disease, or MASH (metabolic dysfunction-associated steatohepatitis, previously dubbed fatty liver)
Articles that list "headache" as a side effect without red-flag guidance leave patients either over-reassured (ignoring thunderclap headache) or over-alarmed (getting MRIs for mild positional headaches)
